TTrialPathMatch Me to Trials
← Back to trials
RecruitingAcute Respiratory Distress Syndrome (ARDS)Acute Lung Injury(ALI)Sepsis Related Acute Lung Injury/Acute Respiratory Distress Syndrome

A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Sepsis is a systemic inflammatory response syndrome triggered by infection, and it is a common critical illness in clinical practice, often leading to multiple organ dysfunction. Among these, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are among the most severe complications. The mortality rate of sepsis-related lung injury is extremely high, reaching 30% - 50%. The existing treatment methods are unable to effectively reduce the high mortality rate of sepsis-related lung injury, and there are no specific treatment measures targeting lung injury itself. Dysbiosis of the intestinal flora plays an important role in the occurrence and development of sepsis-related lung injury. Fecal microbiota transplantation (FMT), as an effective means of regulating the intestinal flora, has shown certain therapeutic potential in some clinical studies. However, current research on FMT for treating sepsis-related lung injury is still in its infancy, and its mechanism is not yet fully clear. The clinical efficacy and safety also lack high-quality evidence support. Therefore, conducting this project's research will provide theoretical basis for targeted microecological treatment of sepsis-related lung injury; establishing a new strategy of combined microbiota transplantation technology for treating patients with sepsis ALI, and providing new ideas and methods for clinical treatment.

Sponsor: Shanghai University of Traditional Chinese Medicine

You may qualify if…

  • Age ≥ 18 years;
  • Clear or suspected infection + SOFA score ≥ 2 points, and PaO₂/FiO₂ ≤ 300 mmHg;
  • Capable of taking in nutrients (able to eat independently or receive enteral nutrition);
  • Voluntarily participate in this trial and sign the informed consent form.

You may not qualify if…

  • Indications for exclusion from FMT (Fecal Microbiota Transplantation) include massive gastrointestinal bleeding, intestinal obstruction, organic intestinal disorders, and severe damage to intestinal mucosa;
  • Individuals with severe immune deficiencies, such as those with AIDS, leukemia, and those using immunosuppressive drugs;
  • Pregnant women and lactating women;
  • Those who cannot undergo nasal-intestinal catheterization or other transplantation methods;
  • Patients who cannot cooperate to complete the study; Other situations where the researchers determine that a patient is not suitable for participating in the clinical trial.

Source: ClinicalTrials.gov · NCT07342205 · last updated 2026-01-15